Serum Lipoprotein-a [Lp(a)] is more associated with Acute Ischemic Stroke than LDL- cholesterol among Nigerian Africans
This study demonstrates that among Nigerian Africans, elevated serum lipoprotein(a) is independently associated with acute ischemic stroke and serves as a stronger predictor than LDL-cholesterol, highlighting its potential significance as a risk marker in this population.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Stroke is a sudden, devastating event that cuts off blood flow to the brain, often leaving behind lasting disability or death. For decades, doctors have looked at the fats circulating in our blood, particularly a type called low-density lipoprotein cholesterol, as the primary warning sign for this danger. This substance, often shortened to LDL, is known to clog arteries and set the stage for heart attacks and strokes. However, a growing body of evidence suggests that for people of African ancestry, the story might be more complicated. While stroke strikes Caucasians later in life, it tends to hit Africans at a younger age, hinting that different or additional risk factors might be at play. One such factor is a particle called lipoprotein(a), or Lp(a) for short. Unlike LDL, which can be lowered by common diet and medication, Lp(a) is largely determined by a person's genes and has been linked to heart disease in other populations, yet its specific role in stroke among Indigenous Africans has remained a mystery.
In a recent study conducted at the University College Hospital in Ibadan, Nigeria, researchers set out to solve this puzzle. They wanted to know if high levels of this genetic particle, Lp(a), were a stronger predictor of acute ischemic stroke—the most common type caused by a clot—than the traditional marker, LDL cholesterol, among Nigerian adults. The team gathered two groups of people: ninety-two patients who had just suffered a confirmed stroke and ninety-two healthy individuals of the same age and sex who had not. By drawing blood from everyone, they measured the levels of both Lp(a) and LDL cholesterol to see which one better distinguished the stroke patients from the healthy controls.
The results painted a clear picture. The patients who had suffered a stroke had significantly higher levels of Lp(a) in their blood compared to the healthy group. On average, the stroke patients had a median level of 88.88 milligrams per deciliter, whereas the healthy controls had a median of just 22.45 milligrams per deciliter. This difference was so distinct that it was highly unlikely to be a coincidence. In contrast, the levels of LDL cholesterol did not show a significant difference between the two groups. When the researchers used statistical tools to isolate the effect of each factor while accounting for other known risks like high blood pressure, diabetes, and smoking, Lp(a) remained a strong, independent link to having a stroke. LDL cholesterol, however, did not hold up as a reliable predictor in this specific group once those other factors were considered.
The study also looked at the specific types of strokes the patients had. Using a standard classification system, the researchers found that nearly half of the stroke cases were caused by disease in the tiny blood vessels of the brain, while others were linked to larger vessels or heart-related clots. Interestingly, the level of Lp(a) did not seem to correlate with how severe the stroke was or which specific type of vessel was affected. This suggests that while Lp(a) is a powerful marker for the risk of having a stroke in this population, it does not necessarily dictate how bad the outcome will be. When the researchers compared the ability of Lp(a) and LDL to identify stroke patients, the genetic particle performed slightly better, further supporting its importance as a risk marker in this context.
These findings suggest that for Nigerians and potentially other people of African descent, the traditional focus on LDL cholesterol might not be telling the whole story. The presence of elevated Lp(a) appears to be a distinct and independent driver of stroke risk in this population. The researchers note that this is a preliminary discovery based on a single hospital in one city, and the numbers involved are modest. They emphasize that these results need to be confirmed in larger groups of people across different regions. However, the study highlights a potential gap in current medical care: if standard cholesterol tests are missing a key risk factor that is common in African ancestry populations, patients might not be getting the full picture of their health. As new therapies emerge that can specifically lower Lp(a), understanding its role in African populations could become crucial for preventing future strokes and saving lives.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.